-
Mashup Score: 0The Stem Cell Transplant Daily - 2 year(s) ago
A selection of articles, blog posts, videos and photos recommended by Muzaffar Qazilbash
Source: paper.liCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1
ClinicalTrials.gov Identifier: NCT02969837.
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1The Stem Cell Transplant Daily - 2 year(s) ago
A selection of articles, blog posts, videos and photos recommended by Muzaffar Qazilbash
Source: paper.liCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1The Multiple Myeloma Daily - 2 year(s) ago
A selection of articles, blog posts, videos and photos recommended by Robert Z. Orlowski
Source: paper.liCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Combination elotuzumab and lenalidomide treatment efficacy is dependent on crosstalk between NK cells, monocytes and myeloma cells - PubMed - 2 year(s) ago
Patients with refractory relapsed multiple myeloma (RRMM) respond to Elotuzumab (Elo) and lenalidomide (Len) combination treatment. The mechanisms underlying this observation are not fully understood. Furthermore, predictive biomarkers of response have not been revealed to date. To address these iss …
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 3Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study - PubMed - 4 year(s) ago
Prolonging overall survival (OS) remains an unmet need in relapsed or refractory multiple myeloma (RRMM). In ELOQUENT-2 (NCT01239797), elotuzumab plus lenalidomide/dexamethasone (ERd) significantly improved progression-free survival (PFS) versus lenalidomide/dexamethasone (Rd) in patients with RRMM …
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet
The latest The Stem Cell Transplant Daily! https://t.co/B2mHHJ6f44 Thanks to @VincentRK @Myeloma_Doc #myeloma #empliciti